must be clearly defined and justified. Regulatory bodies prefer endpoints with a demonstrated correlation to clinical benefit (e.g., progression-free survival, 6-minute walk test).

Sample Size and Statistical Rigor: Even with small populations, the trial must be powered adequately to detect clinically meaningful effects.

Bias Minimization: Independent adjudication of outcomes and blinded assessments can help reduce bias in non-randomized settings.

External Data Integration: Use of real-world evidence, patient registries, or natural history studies enhances the contextual understanding of trial results.

Each of these components must be transparently documented in regulatory submissions, along with assumptions and limitations.

Continue Reading: Regulatory Acceptance, Real-World Case Studies, and Ethical Frameworks

Regulatory Perspectives on Single-Arm Trials

Global regulatory agencies have shown increasing flexibility in accepting single-arm studies for rare diseases when randomized trials are infeasible. Notable regulatory positions include:

• FDA: Accepts single-arm trials under its Accelerated Approval Program, especially for life-threatening rare diseases with unmet medical need. The FDA often requires post-marketing confirmatory studies.
• EMA: Allows single-arm data under Conditional Marketing Authorization, provided the benefit-risk profile is favorable and supported by high-quality external control data.
• Health Canada: Permits single-arm evidence for orphan drugs under its Notice of Compliance with Conditions (NOC/c) policy, often in conjunction with real-world evidence.

Regulatory success depends not only on trial design but also on context—such as disease severity, lack of alternatives, and consistency of observed effects across subgroups.

Real-World Case Study: Zolgensma for Spinal Muscular Atrophy (SMA)

One of the most cited examples of a successful single-arm trial is the approval of Zolgensma (onasemnogene abeparvovec) for SMA Type 1. The pivotal study:

• Included 15 infants treated with a single gene therapy infusion
• Measured motor milestone achievement and survival over 18 months
• Used a historical cohort from a global SMA natural history database as the control

The results showed dramatic improvement in survival and motor function compared to untreated historical controls. The FDA granted Accelerated Approval in 2019 based on these findings, with confirmatory studies ongoing. This case illustrates how well-designed single-arm trials can meet the highest regulatory standards when justified appropriately.

Ethical Justification for Single-Arm Designs

Single-arm studies often carry strong ethical rationale in rare diseases:

• No Standard of Care: Randomization to placebo would deny patients any potential benefit.
• Rapid Disease Progression: Patients may deteriorate rapidly without treatment, making delays unacceptable.
• Small Population Size: Recruiting sufficient patients for multi-arm studies may not be feasible within a reasonable timeframe.
• Patient Advocacy Support: Advocacy groups often endorse single-arm trials to ensure access to promising therapies.

While these factors support the use of single-arm studies, they must be balanced with safeguards to ensure scientific validity and patient protection.

Tools and Methods to Strengthen Single-Arm Studies

Several strategies can improve the robustness and interpretability of single-arm data:

• Propensity Score Matching: Matches patients with external controls to reduce selection bias.
• Bayesian Hierarchical Modeling: Enables borrowing of strength from historical data with quantified uncertainty.
• Blinded Independent Review Committees (BIRCs): Ensure objectivity in endpoint assessments.
• Patient-Reported Outcomes (PROs): Provide qualitative and quantitative evidence of clinical benefit.
• Real-World Evidence (RWE): Supplements trial data and supports post-approval commitments.

These tools are increasingly recognized by regulators and add credibility to single-arm trial submissions.

Regulatory Guidance Documents to Consider

Sponsors designing single-arm trials should consult the following guidelines:

• FDA Guidance on Rare Diseases: Common Issues in Drug Development
• EMA Guideline on Clinical Trials in Small Populations
• India’s CTRI for single-arm orphan trial registration standards

These documents offer insight into endpoint selection, statistical methodologies, and regulatory expectations tailored to rare diseases.

Conclusion: Making Single-Arm Trials Work for Orphan Drug Approval

Single-arm trials are not a shortcut but a scientifically grounded alternative when randomized studies are impractical. In rare diseases, they offer a lifeline for both sponsors and patients—enabling faster access to treatments while preserving ethical integrity.

To gain regulatory acceptance, sponsors must ensure methodological rigor, robust external controls, ethical clarity, and alignment with regulatory frameworks. As more rare disease therapies are developed, single-arm designs will continue to play a pivotal role in global orphan drug approval pathways.